Recent studies have revealed extensive genetic diversity both between and within tumours.
This heterogeneity affects key cancer pathways, driving phenotypic variation, and poses a …

Despite decades of research, brain tumours remain among the deadliest of all forms of
cancer. The ability of these tumours to resist almost all conventional and novel treatments …

Recent therapeutic advances in oncology have been driven by the identification of tumour
genotype variations between patients, called interpatient heterogeneity, that predict the …

Tumor recurrence is a leading cause of cancer mortality. Therapies for recurrent disease
may fail, at least in part, because the genomic alterations driving the growth of recurrences …

The study of cell-population heterogeneity in a range of biological systems, from viruses to
bacterial isolates to tumor samples, has been transformed by recent advances in …

Developments in genomic techniques have provided insight into the remarkable genetic
complexity of malignant tumours. There is increasing evidence that solid tumours may …

The differentiation of tumorigenic cancer stem cells into nontumorigenic cancer cells confers
heterogeneity to some cancers beyond that explained by clonal evolution or environmental …

Recent technologic advances have permitted higher resolution and more rapid analysis of
individual cancer genomes at the single-nucleotide level. Such advances have shown …

The maintenance and repair of many adult tissues are ensured by stem cells (SCs), which
reside at the top of the cellular hierarchy of these tissues. Functional assays, such as in vitro …

Historical risk stratification criteria for medulloblastoma rely primarily on clinicopathological
variables pertaining to age, presence of metastases, extent of resection, histological …